Abeona Therapeutics Inc. ABEO

ZEVASKYN's launch momentum persists, Abeona reports $11.4 million in quarterly net product revenue (up 31% sequential) and 12 treated patients across seven qualified centers as of Aug. 13. Cincinnati Children's joined the network, expanding access to a site among seven centers that cover more than 95% of commercial lives; Medicaid covers ZEVASKYN in all 50 states. Administrative hurdles remain, including prior authorization and single-case agreements that slow treatment, though centers are gaining efficiency; activation can take two months. Abeona estimates about 750 of roughly 1,300 US dystrophic EB patients could be eligible, with a $3.1 million per-treatment-cycle price. Cash runway stands at $146 million to support the commercial launch and ABO-701 development. Beyond ZEVASKYN, partnerships with Ultragenyx and Taysha, plus the PSMA-SIR-T program and preclinical AAV204 licenses, diversify pipeline. Abeona expects roughly two cycles per eligible patient and cash-flow positivity after treating more than three patients in a month. Launch momentum and large potential patient pool with strong cash runway could materially lift revenue trajectory, though reimbursement bottlenecks temper certainty.

Abeona Therapeutics is expanding its ZEVASKYN network as the autologous, one-time cell-sheet therapy for recessive dystrophic epidermolysis bullosa moves toward commercialization. The 84-hour shelf life and tightly coordinated manufacturing require treating centers to synchronize surgeons, anesthesiologists and staff. The qualified-treatment-center network has grown to seven sites across states representing about 40% of the addressable patient population, with more than 100 potential candidates identified. Management says completed treatments—rather than biopsies or manufacturing activity—serve as the key commercial metric. About 95% of commercially insured lives have ZEVASKYN coverage; Medicaid coverage exists in baseline form, and patients face limited copays. Manufacturing turnaround runs about 23–26 days, with an average output of nine sheets per lot. Early demand is expected from new patients; repeat treatments may occur after 6–12 months. Free-cash-flow positivity likely only after more than three patients treated per month. Expansion of treatment centers and coverage, with early demand and path to profitability if volumes materialize.

Abeona Therapeutics congratulates Ultragenyx on U.S. FDA approval of FAYUVI gene therapy for Sanfilippo Syndrome Type A. Ultragenyx FDA approval adds direct competition in Abeona's core Sanfilippo gene therapy area.

ABEO shares rise after approval of a drug previously sold by Abeona and a rating issued for the product it currently sells. Approval of past asset and rating for current product drive short-term stock movement and market attention without reshaping core operations.

Abeona Therapeutics activates University of Florida Health as newest qualified treatment center for ZEVASKYN. New treatment center expands ZEVASKYN access incrementally but does not signal major strategic or financial shift.

Abeona Therapeutics hits a key reimbursement milestone for its gene therapy launch. Reimbursement milestone advances gene therapy launch and supports revenue growth prospects.

Abeona Therapeutics Inc (ABEO) reported a 31% surge in ZEVASKYN revenue in its Q2 2026 earnings call highlights. ZEVASKYN revenue growth of 31% signals strong product adoption and improved financial trajectory for Abeona.

Abeona Therapeutics reports accelerating momentum in the Zevaskyn launch. Zevaskyn launch momentum signals major commercial progress for Abeona's lead product.

Abeona Therapeutics Inc. (ABEO) held its Q2 2026 earnings call covering financial results and operational updates. Quarterly earnings calls deliver performance data and guidance that can shift near-term investor views without guaranteeing major strategic shifts.

Abeona Therapeutics discussed Q2 financial results and pipeline advancements during its earnings call. Q2 earnings call provides financial metrics and outlook that influence near-term valuation.

Abeona Therapeutics reported its second quarter 2026 financial results and issued a business update. Quarterly results and updates supply financial metrics that can shift near-term investor views on company performance.

CMS grants New Technology Add-On Payment status for ZEVASKYN® to Abeona Therapeutics Inc. NTAP status for ZEVASKYN improves Medicare reimbursement and accelerates commercial uptake.

Cincinnati Children's has been activated as the seventh qualified treatment center for Abeona Therapeutics' ZEVASKYN gene therapy, expanding the network available to patients. Addition of one more treatment center incrementally widens ZEVASKYN access and supports commercialization without fundamentally shifting company trajectory.

Abeona Therapeutics treated three patients in 1Q26 and activated two additional Qualified Treatment Centers. Patient treatments and new center activations mark measurable progress toward commercial therapy delivery.

Abeona Therapeutics Inc. released its Q1 2026 earnings call summary covering financial results, operational progress, and forward-looking statements for the company. Quarterly earnings updates provide financial and strategic details that moderately influence near-term market views without major structural changes.

Abeona Therapeutics Inc. (ABEO) reported strong revenue growth in Q1 2026 earnings call highlights, alongside key operational updates and future outlook. Strong revenue growth in Q1 2026 demonstrates significant financial momentum and potential to alter investor sentiment and company trajectory.

Abeona Therapeutics Inc. (ABEO) Q1 2026 earnings call complete transcript released, covering financial results, pipeline updates, and strategic outlook. Earnings call transcripts detail financial performance, clinical progress, and guidance, often driving significant stock volatility and investor reassessment.

Abeona Therapeutics Inc. (ABEO) reported first quarter 2026 financial results and provided an update on its development pipeline. Quarterly financial results combined with pipeline updates signal key progress in clinical development and financial health, potentially shifting investor sentiment and stock trajectory.

Abeona Therapeutics Inc. (ABEO) released Q1 earnings call highlights, detailing financial results, pipeline advancements in gene therapies for rare diseases, clinical trial updates, and strategic outlook. Q1 earnings highlights reveal financial performance and pipeline progress with moderate potential to influence investor sentiment and stock trajectory.

Abeona Therapeutics activates Children's Hospital of Philadelphia as a new Qualified Treatment Center for ZEVASKYN®. Expanding ZEVASKYN's Qualified Treatment Center network with a leading pediatric hospital boosts commercialization potential and investor confidence.

Abeona Therapeutics announces a new Qualified Treatment Center for ZEVASKYN in New York, expanding access to the therapy. Adding a new treatment center expands ZEVASKYN access, potentially boosting patient reach and revenue with moderate impact on operations and sentiment.

Abeona Therapeutics Inc. (ABEO) Q4 2025 earnings call summary covers quarterly financial results, operational updates, and forward-looking guidance. Q4 earnings call summary impacts financial performance and investor sentiment moderately through key operational and pipeline disclosures.

Abeona Therapeutics Inc. (ABEO) experiences building momentum for Zevaskyn®, signaling positive developments in its pipeline. Building momentum for Zevaskyn® represents a major product advancement likely to significantly enhance ABEO's competitive position and investor sentiment.

Abeona Therapeutics Inc. (ABEO) Q4 2025 earnings call highlights strong demand for Zivasskin, signaling robust commercial traction. Strong demand for Zivasskin points to major revenue potential and positive shift in market trajectory for Abeona.

Abeona Therapeutics Inc. (ABEO) released highlights from its Q4 earnings call, covering financial results, pipeline advancements, and strategic outlook. Q4 earnings call highlights detail financials, clinical progress, and guidance pivotal to stock volatility and long-term valuation.

Abeona Therapeutics Inc. (ABEO) Q4 2025 earnings call transcript details financial results, operational updates, pipeline progress, and forward guidance. Q4 earnings transcript discloses financial performance, clinical advancements, and strategic plans directly influencing ABEO's market trajectory and investor sentiment.

Abeona Therapeutics Inc. (ABEO) reported full year 2025 financial results and provided corporate updates. Full-year financial results combined with corporate updates represent major strategic disclosures that can significantly alter investor sentiment and company trajectory.

Abeona Therapeutics Inc. (ABEO) reported Q4 financial results in its earnings snapshot. Q4 earnings snapshots moderately influence financial performance and short-term market sentiment.

Abeona Therapeutics announces ZEVASKYN launch back on track after delays, with profitability targeted for 2026 amid improved manufacturing and commercialization progress. Resuming ZEVASKYN launch and projecting 2026 profitability represent a major strategic advancement for revenue generation and investor confidence.

Abeona Therapeutics provides business update highlighting building momentum in ZEVASKYN commercial launch. Building momentum in ZEVASKYN commercial launch indicates significant progress in Abeona's key product rollout, potentially boosting revenue and investor confidence.